Akorn to Pay $7.9 Million to Resolve Medicare Fraud Claims
Illinois-based generic drugmaker Akorn Pharmaceuticals has agreed to pay $7.9 million to resolve claims that it caused Medicare to be billed for over-the-counter drugs that were not eligible for coverage, Reuters reported. The settlement, announced on Wednesday by the office of Massachusetts U.S. Attorney Rachael Rollins, stems from a 2021 whistleblower lawsuit. Whistleblower Albermarle LLC, an entity formed for the purpose of bringing the lawsuit, will receive about $946,000 of the recovery. The case centers on three drugs: anti-inflammatory cream diclofenac, antihistamine eye drop olopatadine and antihistamine nasal spray azelastine. Until recently, Akorn sold generic prescription versions of these drugs, which were eligible for Medicare reimbursement. Dicolfenac and olopatadine became became available over the counter in February 2020, and azelastine followed in June 2021, meaning the drugs were no longer eligible for Medicare. Rollins' office said that Akorn continued to sell them with obsolete prescription labeling, resulting in false claims for reimbursement being submitted to Medicare. According to Rollins' office, Akorn waited until early 2021 to seek to convert its dicolfenac and olopatadine to over-the-counter, and until January 2022 to withdraw its azelastine from the market, in order to increase profits. Akorn in 2020 filed for bankruptcy after German healthcare company Fresenius SE pulled out of a deal to buy it. The company emerged from bankruptcy following a sale to its lenders.